This relies on the broad impact of MYCN/IGF2BP1-driven gene expression leading to enforced oncogene synthesis, most prominently of Chr 17q genes like BIRC5. In transgenic LSL-IGF2BP1 mouse models, neuroblastoma formation was strictly IGF2BP1 dose-dependent. The gene discussed is MYCN; the disease is neuroblastoma.